Patients in Alabama with qualifying medical conditions are reportedly days away from being able to purchase medical cannabis with a physician’s recommendation, according to dispensary owners and state officials. Callie’s Apothecary in Montgomery is expected to be the first medical cannabis dispensary to open in the state, marking a significant development for patient access.
Program Commencement and Dispensary Operations
Vince Schilleci, owner of Callie’s Apothecary, stated that the Montgomery location is awaiting product delivery and testing before opening. The initial order for products has been placed with a processor, but the exact delivery timeline remains uncertain due to the complexities of shipping and the state’s seed-to-sale tracking system requirements, as reported by Alabama Reflector via AL.com.
When the program is fully operational, Alabama is projected to have 12 dispensaries across the state, managed by four licensed companies. Schilleci emphasised a focus on efficient and compassionate patient service, acknowledging the chronic conditions many patients manage.
Licensing Status and Legal Challenges
John McMillan, Director of the Alabama Medical Cannabis Commission (AMCC), confirmed that three companies—CCS of Alabama, LLC, GP6 Wellness, LLC, and RJK Holdings, LLC—currently hold licenses and anticipate opening their storefronts this summer. A fourth license is subject to ongoing litigation, though it is likely to be awarded to Yellowhammer Medical Dispensaries, LLC.
The implementation of the Alabama medical cannabis law, enacted in 2021, has faced delays due to legal challenges. Some firms initiated lawsuits against the AMCC regarding the licensing process, alleging discrimination. Additionally, a case brought by five parents concerning delays in patient access was dismissed in August.
Patient Access and Product Regulations
The 2021 Alabama medical cannabis law permits registered physicians to recommend cannabis for approximately 15 medical conditions. These conditions include cancer, depression, Parkinson’s Disease, post-traumatic stress disorder (PTSD), sickle-cell anemia, chronic pain, and terminal diseases.
Approved product forms are restricted to tablets, tinctures, patches, oils, and gummies (specifically peach flavor). Raw plant material and smokable forms remain prohibited under the current regulations.
- Patient Registration: Individuals with qualifying conditions must obtain physician approval and register with the AMCC to purchase products. As of Monday, 181 patients were registered with the commission.
- Physician Certification: The Alabama Board of Medical Examiners reported 43 physicians certified to recommend medical cannabis to patients as of Thursday.
- Dispensary Process: Patients will present their “cannabis card” that their recommending physician will give them in order to enter the storefront. They will then sign in and enter a pharmacy-like room where they can receive consultation from dispensary staff and select a cannabis product.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
